Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P0DPD6
UPID:
ECE2_HUMAN
Alternative names:
-
Alternative UPACC:
P0DPD6; A5PLK8; O60344; Q6NTG7; Q6UW36; Q8NFD7; Q96NX3; Q96NX4; Q9BRZ8
Background:
Endothelin-converting enzyme 2 (ECE-2) plays a pivotal role in cardiovascular physiology by converting big endothelin-1 to endothelin-1. Beyond its cardiovascular implications, ECE-2 is instrumental in processing a variety of neuroendocrine peptides, such as neurotensin, angiotensin I, substance P, and peptides derived from proenkephalin and prodynorphin. Its potential involvement in amyloid-beta processing suggests a broader biological significance, hinting at a role in neurodegenerative processes.
Therapeutic significance:
Understanding the role of Endothelin-converting enzyme 2 could open doors to potential therapeutic strategies. Its involvement in the processing of critical peptides and potential role in amyloid-beta processing positions ECE-2 as a target of interest in developing treatments for cardiovascular diseases and possibly neurodegenerative disorders.